Phathom Pharmaceuticals currently has a negative Return on Invested Capital (ROIC) of -53.45%, which is much lower than its Weighted Average Cost of Capital (WACC) of 15.49%, indicating it is destroying shareholder value. This is common in clinical-stage biopharmaceutical companies due to heavy research and development expenses before product commercialization. Among its peers, only Arcutis Biotherapeutics shows a positive ROIC, though still below its WACC, highlighting its relatively better capital efficiency. The trend reflects the financial challenges biotech firms face in balancing innovation costs with value creation.
Imperial Petroleum Inc. shows strong financial health with a Return on Invested Capital (ROIC) of 10.32%, surpassing its Weighted Average Cost of Capital (WACC) of 9.73%. This indicates the company is effectively generating returns above its cost of ...
Outlook Therapeutics announced a $5 million registered direct offering of 8.54 million shares at $0.5855 each to its largest shareholder, GMS Ventures. The proceeds will support working capital and general corporate purposes, including advancing its ...
The Schall Law Firm is investigating Exzeo Group, Inc. for potentially issuing false or misleading statements and failing to disclose important information to investors. This follows Exzeo's announcement of its Q1 2026 financial results on May 6, 202...
Baker Hughes has locked in multi-year contract extensions with Equinor to support offshore hydrocarbon production in the North Sea and expanded its offshore drilling operations in Brazil's Santos Basin through a contract extension with Petrobras. The...
Ford Motor Company announced the launch of Ford Energy, a subsidiary focused on large-scale battery storage systems for utilities, industrial clients, and AI data centers. Morgan Stanley valued this new division at $10 billion, projecting annual EBIT...
